Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Phase 1, Dose-Escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Multiple Cancer Types
Kidney (Renal Cell), Phase I
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.